PAVMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.12 USD | -5.78% |
|
+2.42% | -48.54% |
| May. 07 | Pavmed Inc. Appoints Dennis Matheis to Board of Directors | CI |
| Mar. 27 | Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024 |
Presenter SpeechLishan Aklog (Executives)I call this special meeting of stockholders of PAVmed...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Calendar
2024-05-12
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.12
USD
Average target price
15.38
USD
Spread / Average Target
+625.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.54% | 20M | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| -0.04% | 63.19B | |
| +13.73% | 52.26B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B |
- Stock Market
- Equities
- PAVM Stock
- News PAVmed Inc.
- Transcript : PAVmed Inc. - Shareholder/Analyst Call
